Results of this genomic and molecular study suggest that the lack of spontaneous immune infiltration in some melanomas is not due to lack of tumor antigens.
Patients with BRAF-mutant melanoma who received treatment with MEDI4736 + trametinib + dabrafenib showed robust immune activation and promising objective response rate.
This exploratory study identified several biomarkers suggestive of adaptive immune activity that correlated with better clinical outcomes during nivolumab treatment.
Updated results from a phase Ib dose-expansion study in UBC suggest that the anti–PD-L1 antibody atezolizumab yields greater efficacy in patients with higher expression of PD-L1 on immune cells.
Updated data from the urothelial cohort that demonstrate favorable and durable activity of pembrolizumab.
In this phase Ib study, pembrolizumab demonstrated promising antitumor activity in SCLC with a 35% overall response rate and 25% of patients experiencing a partial response.
Results of phase I study of nivolumab with or without ipilimumab in patients with SCLC and progression on prior therapy.
Results from the CheckMate 017 trial, which led to FDA approval of nivolumab in advanced squamous NSCLC, show 3.2 month improvement in overall survival with fewer adverse events vs docetaxel.
Core faculty, Michael B. Atkins, MD, and Antoni Ribas, MD, PhD, provide their analysis of key immunotherapy presentations from the 2015 clinical oncology meeting in Chicago along with insight from experts David F. McDermott, MD; Daniel P. Petrylak, MD; Naiyer Rizvi, MD; and Heather Wakelee, MD.
In this downloadable slideset, Michael B. Atkins, MD, and Antoni Ribas, MD, PhD, provide their analysis of key immunotherapy presentations from the 2015 clinical oncology meeting in Chicago along with insight from experts David F. McDermott, MD; Daniel P. Petrylak, MD; Naiyer Rizvi, MD; and Heather Wakelee, MD.
Data from this large phase III trial suggest that the combination of nivolumab + ipilimumab offers better efficacy vs ipilimumab alone, but also better efficacy vs nivolumab alone, particularly for patients whose tumors are low in PD-L1 expression.
Results of the first study utilizing tumor genetics to guide use of immunotherapy suggest that genomic instability may be more important than histology in conferring response to anti–PD-1 therapy.
Results of a phase1/2 study of nivolumab monotherapy in patients with advanced hepatocellular carcinoma reveal encouraging 12 month survival rate
Results from the CheckMate 057 trial demonstrate superior OS and favorable safety profile with nivolumab vs docetaxel in patients with advanced nonsquamous NSCLC who failed prior platinum-based doublet chemotherapy.
You are accessing CCO's educational content today as a Guest user.
If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.